ScreenerHero

ZEAL Zealand Pharma A/S

CPH · DK · Healthcare · Biotechnology · zealandpharma.com
265.60DKK-0.11%Mkt Cap: 2.58B $P/E: 6.87

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap2.58B USD
Enterprise Value641.70M USD
Revenue (TTM)676.39M USD
Gross Profit1.34B USD
Net Income (TTM)940.19M USD
Revenue/Share65.97 DKK
Last Price265.60 DKK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees578
CountryDK
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)6.87
P/E (Forward)35.48
PEG—
EV/EBITDA1.90
EV/Revenue0.95
P/S3.82
P/B1.02
EPS (TTM)38.64
EPS (Forward)7.49
52W Range
233.5010% of range556.00
52W High556.00 DKK
52W Low233.50 DKK
Profitability
Gross Margin99.99%
Oper. Margin85.93%
EBITDA Margin50.05%
Profit Margin70.05%
ROE43.52%
ROA40.47%
Growth
Revenue Growth-50.60%
Earnings Growth-47.60%
Cash Flow & Leverage
Operating CF951.39M USD
CapEx (TTM)10.06M USD
FCF Margin-44.44%
FCF Yield-11.63%
Net Debt-2.05B USD
Net Debt/EBITDA-6.04
Balance Sheet
Debt/Equity0.03
Current Ratio13.98
Quick Ratio13.76
Book Value/Sh259.59 DKK
Cash/Share208.33 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 DKK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)416.00 DKK
Upside (mean)+56.6%
Target Range300.00 DKK – 595.00 DKK
300.00+56.6% to mean595.00
# Analysts12
Ownership
Shares Out.66.80M
Float59.41M
Insiders0.53%
Institutions40.92%
Technical
SMA 50300.57 (-11.6%)
SMA 200328.46 (-19.1%)
Beta0.59
S&P 52W Chg14.58%
Avg Vol (30d)399.90K
Avg Vol (10d)417.07K
Technical Indicators
RSI (14)38.4
MACD-9.7692
MACD Signal-9.2383
MACD Hist.-0.5309
BB Upper295.44 DKK
BB Middle276.10 DKK
BB Lower256.75 DKK
BB Width14.02%
ATR (14)12.12 DKK
Vol Ratio (20d)1.10x